Vectura Group plc Notice of Capital Markets Event (3481F)
17 May 2017 - 4:00PM
UK Regulatory
TIDMVEC
RNS Number : 3481F
Vectura Group plc
17 May 2017
Vectura Group plc
Notice of Capital Markets Event
Chippenham, UK, 17 May 2017: Vectura Group plc (LSE: VEC) ("the
Group"), an industry-leading inhaled airways disease focused
business, will hold a Capital Markets Event in London for analysts
and investors in the afternoon, Wednesday 28 June 2017.
The agenda will focus on Vectura's unique integrated inhaled
drug development platform and will include a pipeline overview.
James Ward-Lilley, Chief Executive Officer, will host the event
with members of the Executive Leadership and senior management
teams.
Invitations and a detailed agenda will follow in due course. The
venue will be Etc. Venues, Fenchurch Street, 8 Fenchurch Place,
London, EC3M 4PB.
- ENDS -
Enquiries
Vectura Group plc +44 (0)1249 667700
Andrew Derodra - Chief Financial Officer
Fleur Wood - Director Communications
Elizabeth Knowles - Director Investor Relations and Analysis
Consilium Strategic Communications +44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart / Jessica Hodgson vectura@consilium-comms.com
About Vectura
Vectura, a FTSE250 company listed on the London Stock Exchange
(LSE: VEC), is an industry-leading inhaled airways disease focused
business with proprietary formulation and devices across DPI, pMDI
and "smart" nebulisation platforms. With our extensive range of
technologies, capabilities and collaborations, we believe we can
become a leader in the development of inhalation products,
increasing our ability to help patients suffering from respiratory
diseases. In June 2016 Vectura completed a merger with Skyepharma
PLC.
Vectura has seven inhaled, four non-inhaled and ten oral
products marketed by partners with growing global royalty streams,
and a portfolio of drugs in clinical development, a number of which
have licence agreements with several global pharmaceutical and
biotechnology companies including Hikma, Novartis, Sandoz,
Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Chiesi,
Almirall, Janssen, and Tianjin KingYork.
For further information, please visit Vectura's website at
www.vectura.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCGGUGPAUPMGMQ
(END) Dow Jones Newswires
May 17, 2017 02:00 ET (06:00 GMT)
Vectura (LSE:VEC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vectura (LSE:VEC)
Historical Stock Chart
From Apr 2023 to Apr 2024